Day One Biopharma Faces Fiduciary Probe Over $21.50 Per Share Servier Sale
Day One Biopharmaceuticals' sale to Servier for $21.50 per share is under investigation by Halper Sadeh LLC for potential federal securities violations and breaches of fiduciary duties. The firm warns insiders could receive substantial benefits and terms may limit superior competing offers for shareholders.
1. Proposed Servier Acquisition
Day One Biopharmaceuticals agreed to a $21.50 per share cash sale to Servier, representing a premium over recent trading levels. The deal anticipates closing following shareholder approval and customary regulatory clearances.
2. Investigation and Allegations
Halper Sadeh LLC is probing potential breaches of federal securities laws and fiduciary duties in the transaction, citing concern that insiders may receive disproportionate benefits. The firm also alleges deal terms could restrict superior competing offers, potentially limiting shareholder value.
3. Shareholder Options and Potential Relief
Shareholders are being invited to discuss their rights at no cost under a contingent fee arrangement, with potential relief including increased consideration or additional disclosures. The investigation could lead to litigation aiming to secure better deal terms or compensation.